Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 8/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 4/20 | 0.34 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703012 | 0.76 | S1PR1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL3715604 | 0.72 | CA12 (0.42) | KDM4EALDH1A1POLBMAPTTP53 | |
| SCHEMBL4898554 | 0.70 | MAPT (0.50) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL1418052 | 0.69 | MEN1 (0.46) | ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL6702810 | 0.69 | HDAC1 (0.38) | ALDH1A1POLBMAPT | |
| SCHEMBL5205220 | 0.67 | PPARG (0.43) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL3895747 | 0.66 | LTA4H (0.50) | ALDH1A1POLBLTA4HMEN1KMT2A | |
| SCHEMBL12424300 | 0.66 | KDM4E (0.38) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL6800670 | 0.65 | KMT2A (0.56) | ALDH1A1MEN1KMT2AMAPTTP53 | |
| SCHEMBL5208226 | 0.65 | PPARA (0.44) | KDM4EALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825222-B2 | 2-(4-(2-(2-BIPHENYL-YL-5-METHYL-THIAZOL-4-YL)-ALKOXY)-PHENOXY) -2-METHYL-PROPIONIC ACID DERIVATIVES; ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20040019090-A1 | 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents | ELI LILLY & COMPANY | 2004-01-29 | — | — | US | disclosed |
| EP-1206457-B1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | LILLY CO ELI (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6610696-B2 | Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides) | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030045558-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY & COMPANY LILY CORPORATE CENTER (US) | 2003-03-06 | — | — | US | disclosed |
| WO-2001016120-A9 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | LILLY CO ELI (US) | 2002-07-11 | — | — | WO | disclosed |
| US-6417212-B1 | PHENYLOXAZOLE SUBSTITUTED ON BENZENEOXYPROPIONIC ACID OR ESTERS | ELI LILLY & COMPANY | 2002-07-09 | — | — | US | disclosed |
| EP-1206457-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001016120-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019090-A1 | 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents | SLC5A2, SLC5A1, GLP1R | KDM4E 3004/4885ALDH1A1 617/4885POLB 3283/4885 |
| US-20030045558-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, PPARA, PPARD | KDM4E 4160/4885ALDH1A1 940/4885POLB 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.